Interactions : אינטראקציות

9        DRUG INTERACTIONS
9.1   Propranolol
Concomitant treatment with RIZALT and propranolol is not recommended as propranolol has been shown to increase the plasma AUC of rizatriptan by 70% [see Dosage and Administration (5.3) and Clinical Pharmacology (13.2)].

9.2  Ergot-Containing Drugs
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and RIZALT within 24 hours is contraindicated [see Contraindications (6)].

9.3  Other 5-HT1 Agonists
Because their vasospastic effects may be additive, co-administration of RIZALT and other 5-HT1 agonists within 24 hours of each other is contraindicated [see Contraindications (6)].

9.4  SSRIs/SNRIs and Serotonin Syndrome
Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (7.7)].

9.5   Monoamine Oxidase Inhibitors
RIZALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. A specific MAO-A inhibitor increased the systemic exposure of rizatriptan and its metabolite [see Contraindications (6) and Clinical Pharmacology (13.2)].